Shopping Cart 0
Cart Subtotal
USD 0

Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Adhera is headquartered in City of Industry, California, the US.

Adhera Therapeutics (MRNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Marina Biotech Acquires Prestalia from Symplmed Pharma 12

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13

Venture Financing 14

Marina Biotech Raises USD0.3 Million in Financing Round 14

Partnerships 15

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Marina Biotech Enters Into Co-Development Agreement With Girindus 17

Merger 18

Marina Biotech and IthenaPharma Merges 18

Licensing Agreements 19

Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19

Oncotelic Enters into Licensing Agreement with Marina Biotech 20

LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21

Autotelic Enters into Licensing Agreement with Marina Biotech 22

Marina Biotech Enters into Licensing Agreement with Autotelic 23

Marina Biotech Enters into Licensing Agreement for NOV582 24

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26

Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33

Equity Offering 34

Marina Biotech Raises USD11.7 Million in Private Placement 34

Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35

Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36

Marina Biotech Raises USD6 Million in Private Placement Of Shares 37

Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38

Marina Biotech Completes Private Placement Of Shares For USD 2 Million 39

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For USD 5 Million 40

Debt Offering 41

Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41

Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42

Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43

Asset Transactions 44

Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44

Adhera Therapeutics-Key Competitors 45

Adhera Therapeutics-Key Employees 46

Adhera Therapeutics-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Corporate Communications 48

Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations 48

Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors 49

Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer 50

Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman 51

Jun 26, 2017: Marina Biotech appoints chief commercial officer 52

Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 53

Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 54

Product News 55

03/13/2017: Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 55

Other Significant Developments 56

Apr 05, 2017: Marina Biotech Provides Business Update 56

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adhera Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Marina Biotech Acquires Prestalia from Symplmed Pharma 12

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13

Marina Biotech Raises USD0.3 Million in Financing Round 14

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Marina Biotech Enters Into Co-Development Agreement With Girindus 17

Marina Biotech and IthenaPharma Merges 18

Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19

Oncotelic Enters into Licensing Agreement with Marina Biotech 20

LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21

Autotelic Enters into Licensing Agreement with Marina Biotech 22

Marina Biotech Enters into Licensing Agreement with Autotelic 23

Marina Biotech Enters into Licensing Agreement for NOV582 24

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26

Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33

Marina Biotech Raises USD11.7 Million in Private Placement 34

Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35

Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36

Marina Biotech Raises USD6 Million in Private Placement Of Shares 37

Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38

Marina Biotech Completes Private Placement Of Shares For USD 2 Million 39

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For USD 5 Million 40

Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41

Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42

Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43

Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44

Adhera Therapeutics, Key Competitors 45

Adhera Therapeutics, Key Employees 46

Adhera Therapeutics, Subsidiaries 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Adhera Therapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Adhera is headquartered in City of Industry, California, the US.

Adhera Therapeutics (MRNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Marina Biotech Acquires Prestalia from Symplmed Pharma 12

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13

Venture Financing 14

Marina Biotech Raises USD0.3 Million in Financing Round 14

Partnerships 15

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Marina Biotech Enters Into Co-Development Agreement With Girindus 17

Merger 18

Marina Biotech and IthenaPharma Merges 18

Licensing Agreements 19

Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19

Oncotelic Enters into Licensing Agreement with Marina Biotech 20

LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21

Autotelic Enters into Licensing Agreement with Marina Biotech 22

Marina Biotech Enters into Licensing Agreement with Autotelic 23

Marina Biotech Enters into Licensing Agreement for NOV582 24

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26

Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33

Equity Offering 34

Marina Biotech Raises USD11.7 Million in Private Placement 34

Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35

Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36

Marina Biotech Raises USD6 Million in Private Placement Of Shares 37

Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38

Marina Biotech Completes Private Placement Of Shares For USD 2 Million 39

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For USD 5 Million 40

Debt Offering 41

Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41

Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42

Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43

Asset Transactions 44

Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44

Adhera Therapeutics-Key Competitors 45

Adhera Therapeutics-Key Employees 46

Adhera Therapeutics-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Corporate Communications 48

Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations 48

Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors 49

Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer 50

Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman 51

Jun 26, 2017: Marina Biotech appoints chief commercial officer 52

Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 53

Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 54

Product News 55

03/13/2017: Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 55

Other Significant Developments 56

Apr 05, 2017: Marina Biotech Provides Business Update 56

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adhera Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adhera Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Marina Biotech Acquires Prestalia from Symplmed Pharma 12

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13

Marina Biotech Raises USD0.3 Million in Financing Round 14

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Marina Biotech Enters Into Co-Development Agreement With Girindus 17

Marina Biotech and IthenaPharma Merges 18

Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19

Oncotelic Enters into Licensing Agreement with Marina Biotech 20

LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21

Autotelic Enters into Licensing Agreement with Marina Biotech 22

Marina Biotech Enters into Licensing Agreement with Autotelic 23

Marina Biotech Enters into Licensing Agreement for NOV582 24

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26

Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33

Marina Biotech Raises USD11.7 Million in Private Placement 34

Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35

Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36

Marina Biotech Raises USD6 Million in Private Placement Of Shares 37

Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38

Marina Biotech Completes Private Placement Of Shares For USD 2 Million 39

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For USD 5 Million 40

Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41

Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42

Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43

Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44

Adhera Therapeutics, Key Competitors 45

Adhera Therapeutics, Key Employees 46

Adhera Therapeutics, Subsidiaries 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Adhera Therapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.